New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
16:13 EDTTSROTESARO reports Q2 EPS ($1.03), consensus (87c)
TESARO anticipates achieving the following key objectives during the second half of 2014: Submit the oral rolapitant New Drug Application to the FDA in approximately six weeks; Initiate a clinical trial of IV rolapitant to support the planned future NDA submission for registration following regulatory approval of oral rolapitant; Continue to advance the Phase 3 NOVA trial of niraparib as a maintenance therapy for patients with ovarian cancer and the Phase 3 BRAVO trial of niraparib in breast cancer patients with germline BRCA mutations; Advance the TSR-011 controlled release formulation work and further evaluate the clinical activity of a fractionated dose of TSR-011 in ALK-positive and TRK-positive patients.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
07:44 EDTTSROAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use